In the 1980's a primary focus for intense cardiovascular research
is in the treatment of patients with acute myocardial infarction.
Although the prevalence of this syndrome has been decreasing in the
United States, still over 1.5 million patients develop myocardial
infarction per year. There is about a 20% chance of a North
American male developing myocardial in farction before the age of
65. The in-hospital mortality still remains at ap proximately
10070-15070 and advances in pharmacologic and device therapy have
allowed for the intensification of research in the treatment of
patients with acute myocardial infarction. The following
manuscripts represent the collective efforts of academic in
vestigators in the United States and abroad as well as members of
the phar maceutical industry, and the Food and Drug Administration
to address the issues involved in interventions in the acute phase
of myocardial infarction. State-of-the-art papers addressing
important topics are followed by discus sion sections which have
allowed participants to express their own viewpoints leading to a
consensus opinion. The first part of this Symposium addresses the
models of experimental myocardial infarction followed by the
important issue of how one defines myocardial infarction size. The
latter is extremely important to be certain that endpoints of
therapeutic or device interventions are objective and reproducible.
A detailed description of the pharmacological interventions to
reduce myocardial infarction size as well as newer devices to
effect mechanical and electrical disorders provide an up-to-date
summary of current opinion."
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!